Report

Global medical needles market is projected to witness a CAGR of 6.52% during the forecast period 2024-2031F, growing from USD 8.04 billion in 2023 to USD 13.33 billion in 2031F. Globally increasing rates of chronic illness and lifestyle issues are predicted to drive significant growth in the needle industry. Standard hypodermic needles, commonly called conventional needles, are the most widely used kind of needles for various medical applications. It includes injectable drug and vaccine administration and removal of bodily fluids, such as blood samples for testing.
The main difference between conventional and safety needles is that, although effective, conventional needles lack built-in safety features to avoid needle stick injuries after usage. With incorporated safety measures, safety needles are intended to prevent needle stick injuries, which can spread infectious diseases in patients and healthcare personnel. The healthcare professionals can manually engage these processes, or they can be activated automatically after the injection. Demand for suturing needles will continue to be driven by an increase in surgical operations. The worldwide needle market is predicted to grow due to increased susceptibility of aging population to numerous illnesses. Increasing immunization campaigns will boost injection needle sales, particularly in developing countries. Moreover, increased acceptance of the needles is probably due to growing recognition of the significance of therapeutic injectables for successful therapy. Strict laws governing needle safety and design, however, can restrain industry expansion.
For instance, Concentric needles, a recent product family introduced by medical device manufacturer Rhythmlink International, LLC on October 13, 2023. In accordance with the approved procedures, the concentric needle is available in four sizes or gauges, which differ in needle diameter, length, and color.
Advancements in Drug Delivery to Propel Market Growth
Developments in drug delivery provide a substantial chance to propel the medical needle market forward. As the pharmaceutical industry develops, patient-centric designs which put comfort, safety, and convenience of the users first, are becoming more important. The requirement for needles is being significantly impacted by new drug delivery technologies such as improved syringes, auto-injectors, and pen injectors. Auto-injectors are especially well-adopted for long-term conditions like multiple sclerosis, rheumatoid arthritis, and severe allergic reactions that call for epinephrine. They enable self-administration of premeasured dosages of medication. The ease of use encourages patients to follow their prescription schedules and gives them more control over how their healthcare is managed. Similarly, pen injectors, which are frequently used to provide insulin for the management of diabetes are made portable and easy to use, making use of injections easier for patients. They frequently call for kinds of needles which are short, thin, and less painful for little doses, which is consistent with the current movement in medicine towards less invasive treatments.
Prefilled syringes offer convenience and less pharmaceutical waste, but safety syringes feature built-in safety, safeguarding to minimize needle stick injuries. Needle-based medication delivery systems are becoming more popular due to growing markets for biosimilars and biologics. Since biologics must be supplied by injection due to their complexity and stability requirements, specialized needles that can handle high-viscosity formulations without sacrificing patient comfort are required. Manufacturers in the needle industry need to work closely with pharmaceutical companies and healthcare professionals to take advantage of the opportunity. They need to make sure that their goods fulfill strict quality requirements, work with the newest medicine delivery systems, and improve the patient experience in general. Drug delivery device innovations respond to current market demands and foresee emerging trends. Therefore, in an increasingly inventive and competitive healthcare sector, these improvements can ensure continued growth of needle producers and market presence. For instance, the global contract research, development, and manufacturing organization (CRDMO) WuXi Biologics Co., Ltd. started operating its new pharma product facility, DP5, in Wuxi, China, under Good Manufacturing Practices (GMP) in June 2022. The facility provides pre-filled syringes (PFS) with a variety of volume delivery options.
Advancements in Needle Technology to Drive the Market Growth
The medical needle market is anticipated to be significantly driven by developments in needle technology. The goals of recent technological advancements have been made to minimize tissue harm, increase patient comfort, and lessen pain. These developments are significant elements that will probably encourage the use of sophisticated needles in a range of medical settings. The development of safety needles, which are intended to lower needle stick injuries among medical personnel, is one such improvement. To minimize unintentional injury, these needles have safety features which retract, cover, or blunt the needle after usage.
The creation of ultra-fine needles which are less painful is another inventive innovation. These are especially helpful for individuals who need injections frequently, including diabetics who need to periodically check their insulin levels. The development of needles with specific coatings that enable smoother entry into the skin and lower friction, hence improving patient comfort, has attracted a lot of interest. The needle sector has an excellent opportunity for expansion due to microneedle technology. Micro needles are tiny needles that can be inserted subcutaneously to administer medications or immunizations without causing pain. The technology could enhance the way vaccines are administered and broaden the range of medications for self-consumption, which would make treatment more convenient for patients. Improvements in needle technology is intended to enhance the patient experience and drug adherence by reducing injection-related discomfort. It is important to know while managing chronic diseases since patients may not want to follow treatment plans that require numerous needle sticks. Overall, the worldwide needle market is anticipated to grow rapidly as needle technology advances with characteristics that support safety, comfort, and efficacy, better satisfying the needs of patients and healthcare providers. For instance, Serpex Medical Inc. announced in September 2022 that the Compass Steerable Needles, steerable biopsy needles which allow for accurate access to lung lesions in the intrapulmonary region to enhance lung cancer diagnosis and therapy, had received U.S. FDA 510(k) clearance. The Recon Steerable Sheath must be cleared before removing the compass steerable needles.
Increasing Dominance of Insulin Administration Bolsters Market Growth
The rising prevalence of diabetes significantly drives the expansion of global medical needles market. Diabetes management often requires regular blood glucose monitoring and insulin administration, which involves the frequent usage of medical needles. As the number of diabetes patients increases globally, there is a corresponding rise in demand for insulin pens, syringes, and lancets. The trend is particularly pronounced in regions experiencing rapid lifestyle changes and urbanization, which contributes to the growing incidence of diabetes.
Furthermore, advancements in needle technology, such as the development of fine-gauge needles which minimize discomfort, have enhanced patient compliance and the overall adoption of insulin therapy. These technological improvements cater to the needs of diabetic patients, making self-administration more convenient and less painful. Additionally, increased awareness and early diagnosis of diabetes have led to more consistent use of medical needles for blood glucose testing and insulin delivery. For instance, Accu-Fine, premium pen needles were introduced in May 2022 by Roche Diabetes Care (F. Hoffmann-La Roche Ltd), a leader in the world of integrated personalized diabetes management (iPDM), to help diabetics administer insulin more smoothly and almost painlessly. The goal of this recent invention from Roche Diabetes Care, the company that makes Accu-Chek, was to simplify the insulin delivery procedure for diabetics, improving their ability to manage their condition.
North America to Dominate the Global Medical Needles Market Share
Due to the size of the United States market, North America is anticipated to dominate the global medical needles market. The rising incidence of diabetes, growing prevalence of heart problems, and numerous innovative product approvals in the region are the main drivers propelling the growth of needles market in North America. According to the report of Centers for Disease Control and Prevention, published in July 2022, about 805,000 Americans suffered from heart attacks annually. The most prevalent kind of heart disease, coronary artery disease, affects more than 20.1 million people in the country over the age of 20.
Syringes and needles are necessary for CVD treatments and therapies. Therefore, it is anticipated that the high disease prevalence will aid in the market's expansion. Additionally, the country has a high and rising incidence of diabetes. Syringes and insulin pens are used in the treatment of diabetes. Therefore, rising diabetes prevalence indicates the market expansion. The examined market is expanding as a part of the latest product approvals in the region. For instance, the TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe (PFS) was approved by the US Food and Drug Administration in February 2022 by Takeda Pharmaceutical Company Limited to prevent attacks of hereditary angioedema (HAE). It is anticipated that these factors will support regional market expansion.
Future Market Scenario (2024 � 2031F)
One of the main factors contributing to the anticipated growth of the needles market is the increasing prevalence of chronic disorders, such as cancer and diabetes, and increasing popularity of minimally invasive surgical procedures. A rising population and sedentary lifestyles are factors that will propel the market growth in future. As technology is advancing, we can expect cutting-edge technology in the region. Players in the market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. For instance, Broncus Medical Inc. made an announcement in September 2023 regarding the release of a novel transbronchial needle intended for less invasive diagnostic uses.
The Wellcome Foundation awarded Vaxxas Pty. Ltd. with USD 3.7 million in August 2023 to further develop needle-free typhoid vaccination technology.
Key Players Landscape and Outlook
Several companies are expanding their business by planning and adopting new strategies. They are complying with new strategic initiatives regarding the launch of newly developed medical needles, to help researchers and expand their presence in the market. Product launches, agreements based on contracts, acquisitions and mergers, investments, and partnerships are some through which they are trying to achieve a larger market share.
On September 26, 2023, Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. announced the signing of an Asset Purchase Agreement (APA) to acquire Nephron's InjectEZ specialty syringe manufacturing facility. It includes an agreement to buy next-generation copolymer prefillable syringe systems from Nephron Pharmaceuticals for more than USD 400 million.
The medical equipment manufacturer ICU Medical Inc. announced in January 2022 that it was purchasing Smiths Medical. Vascular access, vital care products, syringe, and mobile infusion devices which are part of the Smiths Medical company.